Creative Biolabs Launches End-to-End Service for Oncolytic Virus Therapy Development and Preclinical Validation
New York, USA - March 19, 2026 - Leveraging its proprietary OncoVirapy™ technology platform, Creative Biolabs now offers one-stop integrated services ranging from foundational viral genetic engineering and rigorous in vitro mechanistic validation to IND-enabling (Investigational New Drug) in vivo preclinical studies.
Bridging the Translational Gap from Early Virus Construction to Clinical Application
The complexity of the modern tumor microenvironment (TME) imposes stringent requirements on the specificity and safety of viral vectors. By combining advanced reverse genetics and bacterial artificial chromosome (BAC) technologies, Creative Biolabs provides customized oncolytic virus therapy development for global clients. This service supports precise gene editing and pathogenicity manipulation (attenuation) of various viral strains, including Adenovirus, Herpes Simplex Virus (HSV), and Vaccinia Virus, thereby achieving enhanced tumor tropism and targeted oncolytic functionality.
Rigorous Analytical Testing and In Vitro Mechanistic Validation
Before advancing to live animal models, ensuring the consistency, purity, and titer of recombinant viral batches is paramount. The company has established a standardized in vitro validation study of oncolytic viruses to clearly elucidate the biological characteristics and mechanisms of action of the virus. The core analytical matrix encompasses electron microscopy for structural analysis, plaque assays for evaluating replication capacity, and functional assays to quantify cytopathic effects (CPE) and transgene expression. These high-density data outputs ensure that only the most potent and stable viral strains progress to downstream development.
IND-Enabling In Vivo Preclinical Pharmacology and Toxicology Studies
Transitioning from the laboratory bench to clinical trials requires comprehensive and compliant safety and efficacy data. Supported by GLP-compliant (Good Laboratory Practice) facilities, Creative Biolabs is equipped to conduct exhaustive in vivo preclinical studies. The research covers immunocompetent mice (to evaluate immune-mediated efficacy), immunosuppressed mice (for direct oncolysis assessment in human xenografts), and non-human primate (NHP) models to rigorously determine acute and chronic toxicity, biodistribution, pharmacokinetics/pharmacodynamics (PK/PD), and the maximum tolerated dose (MTD). This provides a robust scientific foundation for patient stratification and dosing regimens in first-in-human (FIH) trials.
Industry Expert Perspective: Empowering Next-Generation Anti-Cancer Therapies
"In the era of precision medicine, oncolytic viruses are not only required to efficiently lyse malignant cells but are also heavily relied upon as immune vectors to activate the host's systemic anti-tumor immune response," stated a technical director of oncolytic virotherapy at Creative Biolabs. "By seamlessly integrating the R&D process from early viral construction to rigorous in vivo toxicological evaluation, we eliminate the data variability risks clients face when transferring across multiple vendors, delivering high-quality evidence sets ready for immediate IND submission."
Technical Analysis: Core Elements for Ensuring Successful OV Translation
Why is Biodistribution Evaluation Indispensable in the Preclinical Phase? Accurately tracking the in vivo replication and dissemination profile of the virus is critical for preventing severe off-target toxicities. Creative Biolabs utilizes advanced quantitative qPCR and histological imaging technologies to precisely track the dissemination and clearance rates of the virus across organs, providing direct biological references for determining clinical safety doses and administration frequencies.
How are Customized Viruses Optimized for Specific Solid Tumors? Through the One-Stop Enhancement strategy, the R&D team arms the virus with disease-specific promoters and therapeutic transgenes (e.g., cytokines and immune checkpoint inhibitors). This enables the virus to precisely exploit constitutively activated signaling pathways or antiviral defense defects in specific cancers (such as melanoma or hepatocellular carcinoma), achieving a dual-targeted synergistic effect of "oncolysis plus immunity."
Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]
